Abstract
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Current Pharmaceutical Design
Title:Development of Peptide Vaccines in Dengue
Volume: 24 Issue: 11
Author(s): Kavita Reginald, Yanqi Chan, Magdalena Plebanski and Chit Laa Poh*
Affiliation:
- Research Centre for Biomedical Sciences, Sunway University, Bandar Sunway, Subang Jaya, Selangor,Malaysia
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Abstract: Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Export Options
About this article
Cite this article as:
Reginald Kavita , Chan Yanqi , Plebanski Magdalena and Poh Laa Chit *, Development of Peptide Vaccines in Dengue, Current Pharmaceutical Design 2018; 24 (11) . https://dx.doi.org/10.2174/1381612823666170913163904
DOI https://dx.doi.org/10.2174/1381612823666170913163904 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents The New Patient and Responsible Self-Medication Practices: A Critical Review
Current Drug Safety Antiretroviral Treatment of HIV Infection Does Not Influence HIVSpecific Immunity but Has an Impact on Non-Specific Immune Activation
Current HIV Research Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modulation of the Immune Response by the Cholera-like Enterotoxins
Current Topics in Medicinal Chemistry Dietary Carbohydrates that Modulate the Immune System
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design miRNA-146a Improves Immunomodulatory Effects of MSC-derived Exosomes in Rheumatoid Arthritis
Current Gene Therapy Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Development of Betamethasone Dipropionate-Loaded Nanostructured Lipid Carriers for Topical and Transdermal Delivery
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease
Current Protein & Peptide Science Evidence for Up-Regulation of Purinergic Receptor Genes Associating with TRPV1 Receptors and Neurotrophic Factors in the Inflamed Human Esophagus
Current Molecular Medicine PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Current Molecular Medicine Nitric Oxide and its Role During Pregnancy: From Ovulation to Delivery
Current Pharmaceutical Design Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research